NEW YORK, Feb 7 – Bristol-Myers Squibb has agreed to subscribe to LifeSpan Biosciences’ G Coupled-Protein Receptors database, the companies said Wednesday.
The database provides expression and localization information for GPCRs, a large class of cell-surface molecules that act as cellular receptors for many biologically active compounds and pharmaceuticals.
Bristol-Myers Squibb joins fellow pharmaceutical companies Pfizer, Novartis, and Merck as a subscriber to the database.
“This agreement provides Bristol-Myers Squibb with access to human gene expression data in tissues important in health and disease, and will aid our efforts in validating new drug targets,” said Mark Cockett, executive director, functional genomics of Bristol-Myers Squibb in a statement.
Subscribers to the GPCR database receive early access to localization data on GPCR targets, as well as continuous updates to the database.
“LifeSpan’s molecular pathology approach provides the next generation of information that allows pharmaceutical companies to prioritize the best potential drug targets from among the many candidates identified by high-throughput sequencing and gene chips,” said Lifespan CEO Joseph Brown.
LifeSpan was not immediately available for comment.